PATIENT INFORMATION LEAFLET
Agnucaston 20 mg coated tablets
Dry extract of Vitex agnus castus fruit
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor or pharmacist.
Contents of the leaflet
Agnucaston is a herbal medicine for the treatment of premenstrual syndrome (monthly discomfort that occurs before regular menstrual bleeding) in adult women aged 18 years or older.
Do not take Agnucaston
Warnings and precautions
Consult your doctor before taking Agnucaston:
Talk to your doctor if your symptoms worsen during treatment with Agnucaston.
If signs of an allergic reaction are observed, you should stop taking this medicine and contact your doctor immediately (see section 4).
Children and adolescents
There are no relevant reasons for the use of Agnucaston in prepubertal children. Use in pubertal and adolescent children under 18 years is not recommended due to the lack of adequate information.
Other medicines and Agnucaston
Interactions between Agnucaston and dopamine agonists (e.g., some medications used for Parkinson's disease), dopamine antagonists (some medications used to treat schizophrenia, bipolar disorders, nausea, or vomiting), estrogens (e.g., used for hormone replacement therapy), and/or anti-estrogens (e.g., some medications used to treat breast cancer) cannot be ruled out.
Inform your doctor or pharmacist if you are taking, have recently taken, or might take any other medicine. If you visit your doctor or any other healthcare professional, remember to inform them if you are taking or have recently taken any non-prescription medicine.
Pregnancy and breastfeeding
There are no reasons for the use of this medicine during pregnancy. Agnucaston is not recommended during pregnancy. Due to the lack of sufficient data on the use of Agnucaston during breastfeeding, its use is not recommended during breastfeeding.
If you are pregnant or breastfeeding, think you might be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
No studies have been conducted on the effects on the ability to drive and use machines. To date, there is no evidence that the ability to drive and use machines is impaired by the use of Agnucaston. However, the ability to drive and use machines may be impaired in patients who experience dizziness.
Agnucaston contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult them before taking this medicine.
Agnucaston contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per coated tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medicine contained in this leaflet or as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose for adult women over 18 years is 1 coated tablet once a day.
Method of administration
For oral use: Swallow the coated tablets with a sufficient amount of liquid (e.g., a glass of water). Do not chew the tablets.
To achieve an optimal effect with the treatment, continuous use for more than 3 months (even during menstruation) is recommended.
If symptoms persist after continuous use for more than three months, consult a doctor, pharmacist, or qualified healthcare professional.
Pediatric population
There are no relevant reasons for the use of Agnucaston in prepubertal children. Use in pubertal and adolescent children under 18 years is not recommended due to the lack of adequate information (see section 2).
Special populations
No data are available on dosage administration instructions for patients with hepatic or renal impairment. Talk to your doctor before taking Agnucaston in case of renal or hepatic dysfunction.
If you take more Agnucaston than you should
If you have taken more Agnucaston than you should, or if a child has taken this medicine by accident, please contact your doctor or hospital for further instructions.
If you forget to take Agnucaston
Do not take a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
There is a risk of serious allergic reactions such as facial swelling, dyspnea (difficulty breathing), and difficulty swallowing. If you experience any signs of an allergic reaction, stop treatment with Agnucaston and contact your doctor immediately (see section 2).
Other side effects that may occur
(Allergy) skin reactions (such as rash and urticaria), acne, headache, dizziness, gastrointestinal disorders (such as nausea, abdominal pain), menstrual disorders.
The frequency of these side effects is unknown (the frequency cannot be estimated from the available data).
If you experience any other side effects not mentioned above, consult a doctor or pharmacist.
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Agency's online platform: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require any special storage conditions.
Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date is the last day of the month indicated.
Composition of Agnucaston
Appearance of Agnucaston and package contents
Packages with 30 coated tablets
Packages with 60 coated tablets
Packages with 90 coated tablets
Not all pack sizes may be marketed.
The Agnucaston coated tablet is white-gray, round, biconvex, and has a smooth surface. The tablet has a diameter of 9.0 - 9.2 mm.
Marketing authorization holder and manufacturer
BIONORICA SE
Kerschensteinerstraße 11-15
92318 Neumarkt
Germany
Tel 09181 / 231-90
Fax 09181 / 231-265
This medicine has been authorized in the EEA member states with the following names:
Austria Agnucaston forte Filmtabletten
Bulgaria, Denmark Cyclodynon forte
Croatia, France, Poland, Slovenia, Sweden Cyclodynon
Czech Republic Agnucaston pro ženy
Estonia Agnucaston intens
Germany, Luxembourg Agnucaston 20 mg
Hungary Agnucaston Forte 20 mg filmtabletta
Italy Agnucaston
Latvia Agnucaston 20 mg apvalkotas tabletes
Lithuania Agnucaston intens plévele dengtos tabletés
Romania Cyclodynon comprimate filmate
Slovakia Agnucaston forte
Spain Agnucaston 20 mg coated tablets
Date of the last revision of this leaflet: August 2021.